Loading...
Market
What will be the outcome of further investigations into the batch-dependent safety signal of BNT162b2 vaccine by end of 2024?
2
Resolution / Starting Odds
Confirms higher SAE rate in early batches • 25%
Confirms no difference in SAE rates • 25%
Finds other contributing factors • 25%
Inconclusive results • 25%
Official reports from health agencies or peer-reviewed publications
Story
Study Finds Batch-Dependent Safety Signal in BNT162b2 Vaccine Using Swedish Data, SAE Rate 1 in 800
Aug 19, 2024, 12:32 PM
A recent study has replicated findings from Danish data using Swedish data, indicating a batch-dependent safety signal for the BNT162b2 vaccine, developed by Pfizer and BioNTech. The study suggests that early commercial batches may have differed from those used later, resulting in more severe adverse events (SAE) in earlier batches, with an SAE rate of 1 in 800. The replication of these findings calls for further investigation into the causes of these differences. Reporting of adverse events, particularly by healthcare professionals, was notably low in Sweden.
View original story
Similar markets
No issues found • 25%
Minor issues found • 25%
Moderate issues found • 25%
Severe issues found • 25%
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
No changes recommended • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
No change in safety guidelines • 25%
Minor safety warning issued • 25%
Major safety warning issued • 25%
Vaccine approval revoked • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Elements confirmed and deemed unsafe • 25%
Elements confirmed but deemed safe • 25%
Elements not confirmed • 25%
Investigation inconclusive • 25%
Yes • 50%
No • 50%
No significant contamination found • 25%
Contamination confirmed, no recall • 25%
Contamination confirmed, recall issued • 25%
Investigation inconclusive • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%